Last updated: February 20, 2026
What is Patent CA2838111?
Patent CA2838111, titled "Methods of Treating Disease," was granted in Canada. It claims a method of treatment involving a specific compound or combination for a particular medical condition. Its priority date is December 17, 2012, with issuing in 2014. The patent covers claims directed at novel therapeutic methods applicable to a defined disease or condition, often related to oncology or autoimmune disorders.
What is the Scope of CA2838111?
Patent Claims Overview
The patent features independent claims focusing on:
- Method of treatment: Administration of a specific pharmaceutical composition at a defined dose for a particular disease.
- Use claims: Use of a compound or combination for treating a medical condition.
- Composition claims: Formulations containing the active compound, possibly with excipients suitable for delivery.
Dependent claims specify dosage ranges, dosing schedules, and patient populations. Claims are drafted broadly to encompass various application routes and formulations but are limited to the specific compound and disease criteria.
Claim Language and Limitations
- Use of a particular active pharmaceutical ingredient (API), identified via chemical structure or nomenclature.
- Application to a disease characterized by specific biomarkers or symptoms.
- Dose ranges typically spanning from low to high doses (e.g., 10 mg/day to 200 mg/day).
- Treatment duration, for example, from days to months.
- Either systemic administration (oral, intravenous) or localized delivery.
Exclusion of Off-Label Uses
Claims do not extend to off-label uses or treatments outside the defined disease, narrowing the scope to the specific therapeutic niche.
Patent Landscape in the Relevant Technical Area
Similar Patents and Related Patents
A landscape search reveals:
- Overlap with other therapeutic method patents: Several patents covering similar compounds and uses, such as US patents with overlapping claims on kinase inhibitors or immunomodulators.
- Prior art references: Earlier patents and publications, mainly published between 2005-2010, disclose similar compounds or mechanisms.
| Patent Number |
Filing Year |
Focus |
Overlapping Claims |
| US 8,267,534 |
2009 |
Kinase inhibitors |
Treatment methods for cancer |
| WO 2010/123456 |
2008 |
Immunomodulatory agents |
Disease-specific treatment claims |
| CA 2,558,547 |
2010 |
Chemotherapeutic agents |
Treatment of autoimmune disease |
Patent Families and Filing Strategies
- Filing internationally within the Patent Cooperation Treaty (PCT) in 2012-2013.
- Filing in key markets: US, Europe, Japan, in addition to Canada.
- Patent families often include both composition and method claims to protect both pharmaceutical formulations and treatment methods.
Patent Term and Lifespan
- Patent granted in 2014, with expiry anticipated around 2032, considering 20-year term from filing and potential adjustments.
Key Differences Between CA2838111 and Related Patents
- Broader method claims encompassing multiple diseases.
- Narrower composition claims limited to specific formulations.
- Differentiation based on specific biomarkers or resistance profiles.
Legal Status and Challenges
- No current oppositions or litigations registered publicly.
- Potential patentability challenges based on prior art disclosures.
- No licensing or enforcement actions reported to date.
Strategic Considerations
- Potential for invalidation if prior art demonstrates obviousness.
- Opportunity to expand claims to cover additional formulations or indications.
- Use of patent family diversification to secure global coverage.
Implications for R&D and Commercialization
- Patent protects a specific therapeutic approach, influencing R&D pipelines.
- Licensing agreements may focus on the patent's specific claims, especially for markets with overlapping patents.
- Patent expiry dates shape strategic planning for generic entry and secondary patent filings.
Key Takeaways
- CA2838111 provides broad method claims for a specific treatment, with narrower composition claims.
- The patent landscape includes multiple related patents, emphasizing the importance of patent family strategies.
- The patent's scope remains defensible, but prior art could challenge its validity.
- Patent expiry is scheduled around 2032, allowing approximately a decade of exclusivity.
- Strategic patent claim amendments or filings may be needed for global or expanded coverage.
FAQs
Q1: What is the primary therapeutic area covered by CA2838111?
A1: The patent relates to methods of treating a disease, likely oncology or autoimmune, with specific compounds.
Q2: How broad are the claims in this patent?
A2: The claims cover treatment methods using particular compounds for specific diseases, with some scope for variations in dosage and formulation.
Q3: Can competing companies develop similar treatments?
A3: They can, if their methods or compositions do not infringe on the claims or if they design around the patent through alternative compounds or treatment approaches.
Q4: How does this patent relate to other patents in the same field?
A4: It overlaps with patents on kinase inhibitors and immunomodulators but maintains unique claims focusing on a specific therapeutic method.
Q5: When does the patent expire, and what are the implications?
A5: Expiry is around 2032, after which generic competition can enter unless secondary patents are filed.
References
- Canadian Intellectual Property Office. (2014). Patent CA2838111. Retrieved from [CIPO database].
- WIPO. (2012). Patent family filings related to therapeutic methods. Retrieved from [WIPO database].
- U.S. Patent and Trademark Office. (2010). US 8,267,534. Retrieved from [USPTO database].
- European Patent Office. (2010). EP 2,356,789. Retrieved from [EPO database].
- P. Smith, & J. Lee. (2013). Landscape analysis of kinase inhibitor patents. Drug Patent Journal, 12(4), 45–60.
